Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 1;38(1):3-9.
doi: 10.1097/WCO.0000000000001337. Epub 2024 Nov 28.

Current gaps in acute reperfusion therapies

Thanh N Nguyen  1 , Yunyun Xiong  2 , Shuya Li  2 , Mohamad Abdalkader  1 , Hui-Sheng Chen  3
Affiliations
Review

Current gaps in acute reperfusion therapies

Thanh N Nguyen et al. Curr Opin Neurol. .

Abstract

Purpose of review: Advances in intravenous thrombolysis and endovascular thrombectomy have significantly reduced disability and improved outcomes associated with acute ischemic stroke.

Recent findings: An expansion of indications for reperfusion therapies in select groups of patients to permit treatment in an extended time window, with large ischemic core, and with simplified imaging protocols have enabled a broader group of patients access to disability-sparing therapy. Cerebroprotection has had renewed development in the era of acute reperfusion.

Summary: In this review, we highlight recent developments in stroke reperfusion research and related questions that are under study or remain unanswered.

PubMed Disclaimer

References

    1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581–1587.
    1. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008; 359:1317–1329.
    1. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384:1929–1935.
    1. Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, noninferiority trial. Lancet 2022; 400:161–169.
    1. Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, noninferiority trial. Lancet 2023; 401:645–654.